Latest Middle East News

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Noumi Limited has struck a binding deal with major shareholder Arrovest to acquire all remaining shares via a scheme of arrangement, offering shareholders a 12.2% premium amid looming $610 million convertible note maturity.

South32 has outperformed its FY26 production guidance, boosted quarterly sales by 15%, and announced a strategic sale of aluminium assets to Alcoa for up to US$5.6 billion, pivoting towards a base metals-focused portfolio.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

Hazer Group has completed a key commercial-scale hydrogen process design package with KBR, boosting its readiness for large-scale deployment and expanding its project pipeline across multiple sectors and geographies.

Barramundi’s portfolio returned a solid 3.8% gross gain in Q2 2026, driven by strong AI-related infrastructure plays and takeover interest in key holdings, despite sector volatility and profit downgrades in healthcare and logistics.

International Equities Corporation Ltd (ASX:IEQ) posted a modest profit for the June 2026 quarter, reversing prior losses amid a challenging economic backdrop that forced the company to exit its hotel and tourism activities.

Savana’s US Small Caps Active ETF (ASX: SVNP) rose 3.74% in June 2026, underperforming the S&P Small Cap 600 benchmark by 7.69% despite a strong 11.43% rally in US small caps driven by valuation expansion and a stronger US dollar.

ECP Emerging Growth Limited rebounded in the June quarter with a 6.1% portfolio gain and an 8.4% lift in net tangible asset value, driven by strong performances in AI-related holdings and consumer growth stocks.

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.

Mirrabooka Investments reported a 63.6% jump in net profit to $13 million for FY26, boosted by higher investment income and dividends. However, its portfolio lagged the benchmark, dragged down by sector exposures and tech stock de-ratings.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.